 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 February 1998 | Volume 128 Issue 4 | Pages 253-261
Background: Preventing bone loss associated with menopause and aging and maintaining the normal microarchitecture of bone provide important opportunities for the prevention of osteoporosis and fractures.
Objective: To determine the safety and efficacy of alendronate, an aminobisphosphonate, for preventing postmenopausal bone loss.
Design: 3-year double-blind, randomized, placebo-controlled trial.
Setting: 15 osteoporosis centers throughout the world.
Participants: 447 women who had recently experienced menopause (6 to 36 months before study entry).
Intervention: Participants were randomly assigned to one of five regimens: oral placebo; oral alendronate, 1, 5, or 10 mg/d; or oral alendronate, 20 mg/d for 2 years followed by placebo during the third year (20/0 mg/d).
Measurements: Bone mineral density was measured by dual-energy x-ray absorptiometry. Bone turnover and bone quality were assessed with biochemical markers and bone histomorphometry.
Results: Alendronate at 5, 10, and 20/0 mg/d increased bone mineral density from baseline at the lumbar spine, femoral neck, and trochanter by 1% to 4% and in the total body by 0.3% to 1.0%; placebo led to losses of 2% to 4% at these sites. Alendronate, 1 mg/d, attenuated losses relative to those seen with placebo. Alendronate decreased markers of bone resorption to a new steady state by 3 months and decreased markers of bone formation by 6 to 12 months. Bone quality remained normal. At all dosages studied, alendronate had a safety and tolerability profile similar to that of placebo.
Conclusions: In early postmenopausal women, alendronate given for 3 years at dosages of 5 mg/d or greater prevented the loss of bone mineral density at the spine and hip and in the total body. Alendronate seems to be a safe and effective nonhormonal option for prevention of postmenopausal bone loss.
Author and Article Information
for the Alendronate Osteoporosis Prevention Study Group.
ARTICLE
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
For affiliations and current author addresses, see end of text.
For members of the Alendronate Osteoporosis Prevention Study Group, see Appendix.
Grant Support: By Merck Research Laboratories in the form of research grants to the individual study sites.
Requests for Reprints: Michael R. McClung, MD, Oregon Osteoporosis Center, Providence Health System, 5050 NE Hoyt Street, Suite 651, Portland, OR 97213.
Current Author Addresses: Dr. McClung: Oregon Osteoporosis Center, Providence Health System, 5050 NE Hoyt Street, Suite 651, Portland, OR 97213.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. S. Weinstein, P. K. Roberson, and S. C. Manolagas Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy N. Engl. J. Med., January 1, 2009; 360(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Glowacki The Deceiving Appearances of Osteoclasts N. Engl. J. Med., January 1, 2009; 360(1): 80 - 82. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Grundberg, H. Brandstrom, K. C. L. Lam, S. Gurd, B. Ge, E. Harmsen, A. Kindmark, O. Ljunggren, H. Mallmin, O. Nilsson, et al. Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells Physiol Genomics, May 1, 2008; 33(3): 301 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Saag, E. Shane, S. Boonen, F. Marin, D. W. Donley, K. A. Taylor, G. P. Dalsky, and R. Marcus Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis N. Engl. J. Med., November 15, 2007; 357(20): 2028 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Greenspan, J. B. Nelson, D. L. Trump, and N. M. Resnick Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial Ann Intern Med, March 20, 2007; 146(6): 416 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Michaud and S. Goodin Cancer-treatment-induced bone loss, part 2 Am. J. Health Syst. Pharm., March 15, 2006; 63(6): 534 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Karlsson, P. Gerdhem, and H. G. Ahlborg The prevention of osteoporotic fractures J Bone Joint Surg Br, October 1, 2005; 87-B(10): 1320 - 1327. [Full Text] [PDF]
|
|
|
|
|
|
M. R. McClung Osteopenia: To Treat or Not To Treat? Ann Intern Med, May 3, 2005; 142(9): 796 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. McClung, R. D. Wasnich, D. J. Hosking, C. Christiansen, P. Ravn, M. Wu, A. M. Mantz, J. Yates, P. D. Ross, A. C. Santora II, et al. Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4879 - 4885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B J Smith, L L Laslett, K D Pile, P J Phillips, G Phillipov, S M Evans, A J Esterman, and J G Berry Randomized controlled trial of alendronate in airways disease and low bone mineral density Chronic Respiratory Disease, July 1, 2004; 1(3): 131 - 137. [Abstract] [PDF]
|
|
|
|
 |
|
 E. S. Siris, Y.-T. Chen, T. A. Abbott, E. Barrett-Connor, P. D. Miller, L. E. Wehren, and M. L. Berger Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures Arch Intern Med, May 24, 2004; 164(10): 1108 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F Eichner, K. B Lloyd, and E. M Timpe Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment Ann. Pharmacother., May 1, 2003; 37(5): 711 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cryer and D. C. Bauer Oral Bisphosphonates and Upper Gastrointestinal Tract Problems: What Is the Evidence? Mayo Clin. Proc., October 1, 2002; 77(10): 1031 - 1043. [Abstract] [PDF]
|
|
|
|
|
|
H. D. Nelson, M. Helfand, S. H. Woolf, and J. D. Allan Screening for Postmenopausal Osteoporosis: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, September 17, 2002; 137(6): 529 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, V. Robinson, D. Black, J. Adachi, B. Shea, P. Tugwell, et al. II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women Endocr. Rev., August 1, 2002; 23(4): 508 - 516. [Full Text] [PDF]
|
|
|
|
|
|
N. H. Bell, J. P. Bilezikian, H. G. Bone III, A. Kaur, A. Maragoto, and A. C. Santora Alendronate Increases Bone Mass and Reduces Bone Markers in Postmenopausal African-American Women J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2792 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, F. Orio Jr., A. Colao, C. di Carlo, T. Sena, G. Lombardi, F. Zullo, and P. Mastrantonio Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1502 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Johnell, W. H. Scheele, Y. Lu, J.-Y. Reginster, A. G. Need, and E. Seeman Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 985 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Gallagher, D. J. Baylink, R. Freeman, and M. McClung Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4717 - 4726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Bisphosphonates for osteoporosis DTB, September 1, 2001; 39(9): 68 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Johnston Jr, N. H. Bjarnason, F. J. Cohen, A. Shah, R. Lindsay, B. H. Mitlak, W. Huster, M. W. Draper, K. D. Harper, H. Heath III, et al. Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials Arch Intern Med, December 11, 2000; 160(22): 3444 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, and J.-Y. Reginster Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1895 - 1900. [Abstract] [Full Text]
|
|
|
|
|
|
P. Ravn, S. R. Weiss, J. A. Rodriguez-Portales, M. R. McClung, R. D. Wasnich, N. L. Gilchrist, P. Sambrook, I. Fogelman, D. Krupa, A. J. Yates, et al. Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1492 - 1497. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Bauer, D. Black, K. Ensrud, D. Thompson, M. Hochberg, M. Nevitt, T. Musliner, D. Freedholm, and for the Fracture Intervention Trial Research Group Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial Arch Intern Med, February 28, 2000; 160(4): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Hall Update in Geriatrics Ann Intern Med, December 7, 1999; 131(11): 842 - 849. [Full Text] [PDF]
|
|
|
|
|
|
R. Lindsay, F. Cosman, R. A. Lobo, B. W. Walsh, S. T. Harris, J. E. Reagan, C. L. Liss, M. E. Melton, and C. A. Byrnes Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3076 - 3081. [Abstract] [Full Text]
|
|
|
|
|
|
N. F. Col, S. G. Pauker, R. J. Goldberg, M. H. Eckman, R. K. Orr, E. M. Ross, and J. B. Wong Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women Arch Intern Med, July 12, 1999; 159(13): 1458 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ravn, D. Hosking, D. Thompson, G. Cizza, R. D. Wasnich, M. McClung, A. J. Yates, N. H. Bjarnason, and C. Christiansen Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2363 - 2368. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. L. Greenspan A 73-Year-Old Woman With Osteoporosis JAMA, April 28, 1999; 281(16): 1531 - 1540. [Full Text] [PDF]
|
|
|
|
|
|
J. Daley Medical Uncertainty and Practice Variation Get Personal: What Should I Do about Hormone Replacement Therapy? Ann Intern Med, April 6, 1999; 130(7): 602 - 604. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cummings, D. M. Black, D. E. Thompson, W. B. Applegate, E. Barrett-Connor, T. A. Musliner, L. Palermo, R. Prineas, S. M. Rubin, J. C. Scott, et al. Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures: Results From the Fracture Intervention Trial JAMA, December 23, 1998; 280(24): 2077 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Levinson and D. Altkorn Primary Prevention of Postmenopausal Osteoporosis JAMA, December 2, 1998; 280(21): 1821 - 1822. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Prior Perimenopause: The Complex Endocrinology of the Menopausal Transition Endocr. Rev., August 1, 1998; 19(4): 397 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Alendronate for Postmenopausal Women Without Osteoporosis Journal Watch (General), February 27, 1998; 1998(227): 1 - 1. [Full Text]
|
|
